c-Myc is a ubiquitously expressed transcription factor that regulates upward of 10% of all genes. c-Myc is also one of the most commonly dysregulated genes in human cancer through mechanisms as diverse as gene amplification, translocation, and mutation (1, 2) . Many c-Myc-regulated genes are involved in cell growth and size, protein synthesis, and metabolism highlighting the multiple contributions of this transcription factor to normal and abnormal growth. Intriguingly, c-Myc also sensitizes cells to apoptosis in response to growth factor withdrawal (3, 4) and many forms of chemotherapy (5) . This effect is mediated, in part, through the mitochondria-associated apoptotic response and proapoptotic BCL-2 family members (6 -9) . The transforming potential of c-Myc is therefore strongly enhanced when pro-survival molecules such as BCL-2 are also up-regulated.
c-Myc is a very labile protein, with an estimated half-life of 20 min (10) . Mutations interfering with c-Myc degradation have been identified in tumor cells reinforcing the importance of turnover in regulating c-Myc protein levels (10) . c-Myc degradation is mediated by the ubiquitin-proteasome degradation pathway (11) . Proteasome inhibitors represent a new class of anti-cancer agent with demonstrated efficacy in myeloma and broad activity in a range of other cancer types (12) . Because c-Myc overexpression sensitizes cells to apoptosis, and the protein is subject to degradation by the proteasome, it is possible that c-Myc acccumulation could contribute to cell death associated with proteasome inhibitors. Watt and Molloy (13) and Small et al. (14) reported that c-Myc is also degraded by calpains, ubiquitous Ca 2ϩ -dependent cysteine proteases. However, the role of c-Myc in the cellular response to calpain or proteasome inhibition is not known. We have investigated the c-Myc dependence for cell death associated with inhibition of these proteases. Here we report that although c-Myc does not contribute significantly to apoptosis mediated by the proteasome inhibitor epoxomycin, it greatly sensitizes cells to calpain inhibitor PD150606-mediated cell death. Calpain activity is regulated by c-Myc and contributes to its growth regulatory properties. Furthermore, knockdown of the calpain negative regulator calpastatin in c-Myc-negative cells results in enhanced cell growth, emergence of anchorage independence, and tumorigenicity, suggesting that calpain promotes transformation in the absence of c-Myc.
EXPERIMENTAL PROCEDURES
Cells and Cell Culture-c-Myc-negative rat-1-derived HO15.19 cells (c-Myc-negative) and HO15.19-derived HOmyc3 cells expressing c-Myc (c-Myc-positive) (15) were cultured in DMEM 2 H21 medium supplemented with 10% FBS (Invitrogen). Human HL60 promyelocytic leukemia cells were cultured in RPMI 1640 medium supplemented with 10% FBS. All cultures contained antibiotics. Small Interfering RNA Transfection-HO15. 19 and HOmyc3 cells were incubated in DMEM H21 medium supplemented with 10% fetal bovine serum at 37°C in a humidified 5% CO 2 incubator. Transfection of siRNA was carried out by using HiPerFect transfection reagent (Qiagen) as described by the manufacturer. The sequence for rat calpastatin was 5Ј-CUC CUU UGG AGA UGC UAA-3Ј. To maintain levels of intracellular siRNA, a second transfection was performed 5 days following the first transfection. The sequence used for rat CPNS1 was 5Ј-GGAGCAUGGUG-GCUGUUAU-3Ј. Cell viability and calpain activity was measured 48 h after transfection.
Growth of Cells in Semisolid Media-The ability of cells to grow in medium containing methylcellulose was tested according to procedure of Wright et al. (16) . Cells were suspended in a mixture of 10% fetal bovine serum, 90% DMEM H21, and 1.2% methylcellulose at densities of 1 ϫ 10 4 , 4-5 ϫ 10 3 , and 0.5 ϫ 10 3 cells per 2 ml of medium. This mixture was layered onto a 2.5-mm plate containing 1 ml of 0.3% agar and DMEM H21 supplemented with 20% fetal bovine serum. Cultures were scored for growth after 2 weeks. Only colonies visible without magnification were counted.
Apoptosis-Cells were treated with the indicated concentrations of PD150606 or epoxomycin (Calbiochem). After 12-18 h, cells were washed twice with PBS containing 2% FBS and stained with CY-5-conjugated annexin V and propidium iodide for 15 min. Samples were analyzed in the LSR II (BD Biosciences).
Adhesion Assay-1 ϫ 10 6 cells were seeded in 6-well plates. After overnight culture, cells were treated with 100 M PD150606. The number of detached cells was counted with a hemocytometer after the indicated incubation times.
Calpain Activity-Calpain activity was measured by flow cytometry as described previously (17) . Cells were trypsinized, washed, counted, and used at a concentration of 1 ϫ 10 7 cells/ml. The same cell concentration was used for HL60 cells. All measurements were performed on an LSR-II (BD Biosciences). The cells were maintained in a temperature-controlled water jacket set at 25°C. Filters were set for the Lightwave Xcyte (UV) laser, excitation line 355 nm, and laser power 25 milliwatts, emission of 405 and 450 nm for substrate and product, respectively. Band pass filters for substrate and product were 405/20 and 450/20. Long pass filters for substrate and product were chosen at 405 and 450. The photomultiplier tube voltage was set on 350 -375 for substrate and 325-350 for the product. To ensure reproducible results, the LSR-II was calibrated before each series of measurements with AlignFlow and AlignFlow plus fluorescent beads (Invitrogen). The photomultiplier tube voltage was adjusted to place the peak of the bead fluorescence histogram in the same channel prior to every experiment. The acquisition (threshold) rate of 250 -280 events/s was chosen, and the sample was delivered at a low sample delivery rate. The calpain substrate BOC-LM-CMAC (10 M unless otherwise indicated) was added after 30 s, and kinetic data were collected for the indicated time.
Western Blotting-Calpains 1 and 2, calpastatin, c-Myc, and CPNS1 expression were measured by Western blot analysis. Cells were lysed in triple lysis buffer containing 1 mM phenylmethylsulfonyl fluoride, 250 M phosphatase inhibitor, and protease inhibitor mixture (Calbiochem). Proteins were subjected to 10% SDS-PAGE, transferred to nitrocellulose membrane, immunoblotted with anti-c-Myc monoclonal antibody clone 9E10, anti-calpastatin monoclonal antibody 1F7E3D10 obtained from Sigma, CPNS1-specific antibody 28239 (Abcam), or rabbit polyclonal anti-calpain 1 and 2 (Sigma). Membranes were then probed with a horseradish peroxidaseconjugated secondary antibody and reacted with ECL reagent (Amersham Biosciences), and signals were detected by medical film processor. The primary antibodies were used at the 1:2,000 dilutions.
Measurement of Intracellular Calpastatin Levels by Flow Cytometry-10
5 cells were fixed in 4% paraformaldehyde at room temperature and then were permeabilized with 0.5% saponin for 20 min. Anti-calpastatin antibody was added for 15 min. Cells were washed three times in PBS supplemented with 2% FBS, and the phycoerythrin-conjugated secondary antibody was added for 15 min. After washing, the cells were analyzed by flow cytometry on the LSRII.
Extracellular Fibronectin Staining-Cells were plated overnight on sterile coverslips and were washed twice with PBS at 37°C. Cells were fixed with 3.7% paraformaldehyde for 15 min at room temperature. After washing twice with PBS, cells were blocked with 5% bovine serum albumin/PBS for 1 h. Primary antibody against fibronectin (IST-9; Abcam) was added to each coverslip at a final concentration of 1:500, and cells were incubated for 2 h in a humidified environment. Excess antibody was washed twice with PBS, and secondary antibody was added to final concentration of 1:10,000 for 30 min. Stained cells were washed and analyzed by fluorescent microscopy (Leica Leitz DM RBE). Images were collected using the Leica Application Suite (version 2.5.0 R1) for 1.3 s. Images were cropped but otherwise unmanipulated.
Lentiviral Vector Construction and Infection-The empty lentivirus vector pLEN (H1GFP), which uses the H1 promoter to drive the expression of shRNA sequences, was a gift from Dr. John Dick (University Health Network, Toronto, Canada). The sequences of the shRNAs used were as follows: human c-Myc 1330, 5Ј-TAA GAT GAG GAA GAA ATC GAT GTG GAT CCA CAT CGA TTT CTT CCT CAT CTT TTT-3Ј and 5Ј-CTA GAA AAA GAT GAG GAA GAA ATC GAT GTG GAT CCA CAT CGA TTT CTT CCT CAT CTT AAT-3Ј; and human c-Myc 917, 5Ј-TAA ACG ACG AGA CCT TCA TCA AAG GAT CCT TTG ATG AAG GTC TCG TCG TTT TTT-3Ј and 5Ј-CTA GAA AAA ACG ACG AGA CCT TCA TCA AAG GAT CCT TTG ATG AAG GTC TCG TCG TTT AAT-3Ј. The oligonucleotide sequences for rat calpastatin shRNA were as follows: rat calpastatin 513, 5Ј-TAA CAA GGT GGT TGT TAA GTC AAG GAT CCT TGA CTT AAC AAC CAC CTT GTT TTT-3Ј and 5Ј-CTA GAA AAA CAA GGT GGT TGT TAA GTC AAG GAT CCT TGA CTT AAC AAC CAC CTT GTT AAT-3Ј; rat calpastatin 2088, 5Ј-TAA GGA TGA AGA TGC AAC ATA AAG GAT CCT TTA TGT TGC ATC TTC ATC CTT TTT-3Ј and 5Ј-CTA GAA AAA GGA TGA AGA TGC AAC ATA AAG GAT CCT TTA TGT TGC ATC TTC ATC CTT AAT-3Ј.
Each pair of oligonucleotides were mixed, annealed by incubating at 95°C for 5 min, and cooled slowly. The annealed mixture was ligated into pLEN vector that had been digested with PacI and XbaI.
Lentivirus vectors harboring shRNA were produced by transient transfection into 293T cells as described previously (18) . Briefly, the backbone plasmid vector construct (10 g) was mixed with the accessory plasmids VSVG (3.5 g), pRRE (6.5 g), and pREV (2.5 g) and transfected into 293T cells using the Calphos mammalian transfection kit (Clontech). The cell supernatant was replaced with 4 ml of fresh Iscove's minimum Eagle's medium (10% fetal calf serum) after 24 h, and virus was harvested at 48 h after the plasmid transfection. 1 ϫ 10 5 HL60 cells or c-Myc-negative rat fibroblasts were co-infected with 2 ml of lentivirus culture supernatant (ϳ2 ϫ 10 6 virus particles) from both shRNA viruses in the presence of 8 g/ml Polybrene (Sigma) for 4 days. Green fluorescent-positive cells were sorted by fluorescence-activated cell sorter and cultured in RPMI (10% fetal calf serum) for further analysis. Because knocked down cell cultures tended to regain c-Myc expression after several weeks, all analysis reported here was performed on cells knocked down within 3 weeks of infection.
Cell Cycle Analysis-1 ϫ 10 5 cells (c-Myc-positive cells, c-Myc-negative cells infected with lentiviral vector control, or c-Myc-negative cells infected with calpastatin-specific shRNAs 513c ϩ 2088-1) were seeded in 6-well plates overnight in DMEM H21 supplemented with 10% FBS and then were washed twice with PBS. Cells were washed, and fresh DMEM H21 with 10% FBS was added for 16 h. Cells were trypsinized and were fixed in 70% cold ethanol. The next day, cells were resuspended in PBS, 2% FBS, 20 g/ml propidium iodide, and 10 units/ml RNase in the dark for 20 min. Fixed cells were examined by flow cytometry (LSRII, BD Biosciences) by initially gating on an area versus width propidium iodide dot plot, used as doublet discrimination. 10,000 cells were collected with a low flow rate (200 events/s). The data were analyzed using the Dean/Jett/Fox method of FlowJo (TreeStar) to determine cell cycle distribution.
Tumor Growth-2088-1 ϩ 513c infected c-Myc-negative cells, vector only c-Myc-negative cells, and c-Myc-positive cells were grown in the DMEM H21 medium supplemented with 10% FBS. When cells were 70 -80% confluent, the cells were washed twice with PBS, trypsinized, and resuspended in fresh medium with no FBS to a final concentration of 1.0 ϫ 10 6 /ml. 3 ϫ 10 4 cells were injected subcutaneously into lower flank of SCID mice, and tumor growth was followed over time. The volume of the tumor was calculated by the following formula: volume ϭ (width) 2 ϫ length/2 every 10 days. Mice were also monitored for any signs of disease or distress.
Statistics-Where reported, error bars are standard errors of duplicate or triplicate measurements. Statistical significance was determined by t tests or analysis of variance as appropriate. *, p Ͻ 0.05, **, p Ͻ 0.01, ***, p Ͻ 0.001. All experiments are representative and were repeated at least twice with similar results.
RESULTS

c-Myc-dependent Apoptosis by Calpain but Not Proteasome
Inhibition-To investigate the role of c-Myc in sensitizing cells to protease inhibition, we exposed c-Myc-negative or c-Mycpositive rat fibroblasts to a proteasome or calpain inhibitor and measured induction of apoptosis. As shown in Fig. 1A , both the proteasome inhibitor epoxomycin and the calpain inhibitor PD150606 (19) induced apoptosis in c-Myc-expressing cells. However, only epoxomycin induced equivalent levels of apoptosis in c-Myc-negative cells. Apoptosis measurements at higher and lower concentrations of epoxomycin also showed no significant differences between c-Myc-negative and c-Mycpositive cells (not shown). In contrast, PD150606 had a much reduced effect in c-Myc-negative cells, inducing apoptosis significantly above background only at the highest concentration tested. This observation therefore indicates that although the ability of epoxomycin to induce apoptosis is c-Myc-independent, PD150606 induces apoptosis in a c-Myc-dependent manner. This observation prompted us to further investigate the relationship between c-Myc and calpain and calpain inhibitormediated cell death.
Increased Calpain Activity in c-Myc-expressing Cells-Calpains are a ubiquitously expressed family of Ca 2ϩ -dependent cysteine proteases. Structurally, calpains consist of a large catalytic subunit of which the best known are calpains 1 and 2 (also known as -calpain and m-calpain), and the common small subunit CPNS1 (also known as CAPN4). Calpains are also negatively regulated by the endogenous inhibitor calpastatin. As shown in Fig. 1C , calpain 2 was expressed in c-Myc-negative and -positive cells; however, the highest level of protein was observed in c-Myc-negative cells. Calpain 1 was detected in c-Myc-negative cells but not in c-Myc-positive cells. In contrast to the expression data, calpain activity was observed to be high in c-Myc-positive cells and practically undetectable in c-Mycnegative cells (Fig. 1B) . It should be noted that calpains undergo autolysis (20, 21) , which may explain the lower level of detectable protein in cells with high activity.
The observation of a correlation between c-Myc expression and calpain activity further suggested that c-Myc may control calpain activity. Calpain activity is regulated, in part, through the endogenous inhibitor calpastatin. As shown in Fig. 1D , calpastatin protein was detected by Western blot in c-Myc-negative cells but not in c-Myc-positive cells. A similar difference in expression was observed when intracellular calpastatin expression was analyzed by flow cytometry (Fig. 1E ). This observation is consistent with previous gene expression profile studies that identified calpastatin as a gene negatively regulated by c-Myc (22, 23) and suggests that c-Myc expression may increase calpain activity through its regulation of the calpain inhibitor calpastatin.
c-Myc Knockdown in HL60 Cells Leads to Decreased Calpain Activity-To further confirm the relationship between c-Myc and calpain activity in an independent cell type, we reduced c-Myc levels in HL60 promyelocytic leukemia cells using lentivirus-mediated shRNA and determined its effect on calpain activity. Although HL60 cells are strongly dependent on c-Myc for autonomous growth, we were able to decrease c-Myc levels significantly below control levels. As shown in Fig. 2A , c-Mycspecific shRNA reduced c-Myc protein levels by 67% compared with vector controls. Calpain activity was observed to be reduced in the knockdown cells by 71% (Fig. 2B ) suggesting a direct relationship between c-Myc levels and calpain activity. When calpastatin expression was measured, we observed increased calpastatin levels in c-Myc knockdown cells (Fig. 2C ) consistent with the observed decrease in calpain activity. We also observed a modest but significant increase in calpain 1 and 2 protein levels in c-Myc KD cells (Fig. 2D ). This observation is consistent with accumulation of calpain protein because of decreased activity and therefore decreased autolysis. Furthermore, decreased c-Myc levels also resulted in decreased sensitivity to PD150606 (Fig. 2E ) but did not alter sensitivity to epoxomycin, consistent with epoxomycin-induced cell death being c-Myc-independent. Taken together, these observations indicate that calpain activity and sensitivity to the calpain inhibitor PD150606 correlate with c-Myc levels in HL60 cells.
CPNS1 Knockdown Induces Apoptosis in c-Myc-positive but Not c-Myc-negative Cells-The results described above indicate that c-Myc sensitizes cells to calpain inhibition by PD150606. To further confirm the role of c-Myc in sensitizing cells to loss of calpain activity, we treated c-Myc-positive and -negative cells with siRNA specific for CPNS1, the regulatory calpain small subunit 1. As shown in Fig. 3A , c-Myc-negative cells expressed higher levels of CPNS1 than c-Myc-positive cells, consistent with the increased levels of calpains 1 and 2 observed in these cells. As also shown in Fig. 3A , siRNA treatment resulted in significant decreases in CPNS1 protein levels. Furthermore, this loss of CPNS1 resulted in suppression of calpain activity in c-Myc-positive cells (Fig. 3B) . To evaluate the consequences of CPNS1 knockdown, induction of apoptosis in c-Myc-positive and -negative cells was measured. Some cells were also incubated with PD150606, together or singly. As shown in Fig. 3C , extensive apoptosis was observed in c-Mycpositive cells treated with CPNS1-specific siRNA, whereas no apoptosis was observed in similarly treated c-Myc-negative cells. Furthermore, the combination of both siRNA and PD150606 resulted in less than additive effects on apoptosis, consistent with their targeting of a common pathway. These observations therefore support the hypothesis that c-Myc sensitizes cells to calpain inhibition.
Calpastatin Knockdown in c-Myc-negative Cells Restores Calpain Activity-The results described above indicate that c-Myc regulates calpastatin expression, which may be responsible for suppressing calpain activity in c-Myc-negative cells. To confirm this mechanism, we used siRNA to knock down expression of calpastatin in c-Myc-negative cells. As shown in Fig. 4A , calpastatin-specific siRNA knocked down protein expression of the inhibitor in a dose-dependent manner. Furthermore, with a second siRNA transfection to maintain the knockdown, this resulted in the restoration of calpain activity over a period of 5-10 days (Fig. 4, B and C) . These observations therefore confirm that calpastatin is responsible for suppressing calpain activity in c-Myc-negative cells.
c-Myc-negative Cells Knocked Down for Calpastatin Remain
Fibronectin Protects c-Myc-expressing Cells from Calpain Inhibition-As described above, we observed that c-Myc-expressing cells, but not c-Myc-negative cells, exposed to PD150606 (Fig. 1A) or CPNS1-specific siRNA (Fig. 3C) underwent apoptosis. In the course of performing these experiments, we noted that c-Myc-expressing cells exposed to PD150606 detached from the plate, although c-Myc-negative cells did not. To better characterize this phenomenon, we plated c-Myc-positive and -negative cells and then exposed the cells to PD150606. We then collected the culture medium and counted the cells. As shown in Fig. 6 , c-Myc-positive cells detached from the plate in increasing numbers after exposure to PD150606, although c-Myc-negative cells did not. This suggested that cell detachment was correlated with induction of apoptosis, possibly through an anoikis-based mechanism (24, 25). Crouch et al. (26) had previously reported that fibronectin could protect c-Myc-expressing cells from serum withdrawal. Furthermore, a variety of proteins associated with focal adhesions, including focal adhesion kinase (27) , paxillin, spectrin, and talin, are potential calpain substrates (28, 29) . In addition, it has also been reported previously that c-Myc negatively regulates fibronectin expression (22, 30, 31) . We therefore investigated whether fibronectin could protect c-Myc-expressing cells from calpain inhibition. We first confirmed that fibronectin expression was regulated by c-Myc. As shown in Fig. 7A , c-Myc-positive cells had significantly less detectable fibronectin than c-Myc-negative cells. Next, c-Myc-positive cells were incubated in plates pre-coated with fibronectin and then exposed to increasing concentrations of calpain inhibitor PD150606. We observed that cells incubated in fibronectin-coated plates did not detach from the plastic when exposed to PD150606 (not shown). Furthermore, as shown in Fig. 7B , the cells were strongly protected from PD150606-induced apoptosis by fibronectin. To confirm these results, we again used siRNA to knock down expression of CPNS1 in c-Myc-positive cells. As shown in Fig. 7C , knock- down led to decreased calpain activity in a dose-dependent manner. Furthermore, as shown in Fig. 7D , loss of calpain activity was associated with loss of cell viability when cells were cultured in the absence of added fibronectin. In contrast, cells cultured on fibronectin maintained viability. These observations further link loss of cell adhesion with apoptosis in response to calpain inhibition. They also suggest that fibronectin-mediated adhesion and signaling is susceptible to calpain inhibition.
Calpastatin Knockdown in cMyc-negative Cells Enhances Cell Growth-As described above, knockdown of calpastatin in c-Mycnegative cells resulted in the restoration of calpain activity in cells. In the course of performing these experiments, we noted a change in cell growth characteristics. To characterize this phenomenon, we measured the growth kinetics of these cells. As shown in Fig. 8A , restoration of calpain activity in c-Myc-negative cells by calpastatin knockdown was also associated with an increase in cell growth rate suggesting that restoration of calpain activity can complement, in part, the cell growth defect characteristic of c-Myc-negative cells.
Calpastatin Knockdown in c-Mycnegative Cells Alters Cell Cycle
Distribution-A characteristic of c-Myc-negative cells is a shift in cell cycle distribution toward an excess of cells in G 0 /G 1 (32) . Given our observation that calpastatin knocked down cells exhibited greater cell growth rates, we investigated whether the cell cycle distribution was altered. We knocked down calpastatin in c-Myc-negative cells using lentivirus-mediated shRNA to maintain the knockdown. As with siRNA-treated cells, the cells knocked down with lentiviruses also displayed increased calpain activity (not shown). As shown in Table 1 , as observed previously, an increased fraction of c-Myc-negative cells was in the G 0 /G 1 phase of the cell cycle. In contrast, calpastatin knocked down cells exhibited a significant shift in the distribution toward S phase with a distribution similar to that of c-Myc-positive cells. This finding suggests that restoration of calpain activity relieves the G 1 /S block in c-Myc-negative cells allowing passage through the cell cycle.
Calpastatin Knockdown in c-Myc-negative Cells Confers Anchorage Independence-A characteristic of c-Myc-transformed fibroblasts is the ability to grow in semi-solid media in an anchorage-independent fashion. To test the ability of calpastatin-knocked down, c-Myc-negative cells to grow in semisolid media, c-Myc-negative cells were treated with siRNA to calpastatin, and the cells were plated in agar. As shown in Fig.  8B , c-Myc-negative cells were unable to grow in agar at any cell density tested. In contrast, c-Myc-negative cells treated with calpastatin-specific siRNA formed distinct colonies in agar in a cell number-dependent fashion (Fig. 8, B and C) . These results indicate that calpastatin and thus calpain also regulate anchorage-independent growth.
Calpastatin Knocked Down Cells Display Increased Tumorigenicity-
The increased growth rate, altered cell cycle distribution, and anchorage-independent growth of calpastatin knocked down, c-Myc-negative cells are all characteristic of c-Myc-mediated transformation and suggested that these cells may also display enhanced tumorigenicity. To examine this possibility, we tested the tumorigenicity of c-Mycnegative cells knocked down for calpastatin expression by lentiviral shRNA. As shown in Fig. 8D , calpastatin knocked down cells were able to generate tumors in SCID mice with growth characteristics that were initially delayed but then became similar to that of c-Myc-expressing cells. This observation therefore indicates that restoration of calpain activity by knocking down calpastatin promotes transformation in c-Myc-negative cells.
DISCUSSION
c-Myc is one of the most commonly dysregulated oncogenes in human cancer. c-Myc dysregulation leads to a variety of oncogenic events, including cell cycle alterations, altered cellular metabolism, and anchorage independence. Concurrently, c-Myc overexpression can also sensitize cells to apoptosis. Here we have investigated the role of c-Myc in sensitizing cells to intracellular protease inhibitors. We observed that the proteasome inhibitor epoxomycin induced apoptosis in a c-Myc-independent manner, whereas the calpain inhibitor PD150606 or CPNS1 knockdown induced apoptosis in a c-Mycdependent manner. Calpain inhibitor-induced apoptosis was associated with cell detachment suggesting an anoikis phenomenon. Plating cells on fibronectin-coated plates prevented cell detachment and protected cells from apoptosis supporting this model. c-Myc expression was correlated with an increase in calpain activity, whereas knockdown of c-Myc expression in HL60 cells led to decreased calpain activity. Knockdown of the endogenous calpain inhibitor calpastatin in c-Myc-negative cells led to a restoration of calpain activity. Surprisingly, restoration of calpain activity was associated with an increase in cell growth, redistribution through the cell cycle, emergence of anchorage independence, and tumorigenicity in immune-compromised mice. However the cells remained relatively insensitive to calpain inhibitor-induced apoptosis. Taken together, these results implicate calpain activation as a mediator of c-Myc-induced cell growth stimulation, show that calpastatin knockdown promotes transformation in c-Myc-negative cells, and suggest calpain as a potential target for c-Myc-transformed cells.
The mechanism by which proteasome inhibitors target cancer cells is incompletely understood. However, a variety of proteasome targets that influence sensitivity have been identified, including NFB (through IB), p53, pro-apoptotic BCL family members, p27, and endoplasmic reticulum stress markers (33) . Orlowski et al. (34) showed that rat embryonic fibroblasts transformed with both ras and c-Myc and CB33 lymphoblas- 
TABLE 1
Cell cycle distribution in c-Myc-negative calpastatin KD cells toid cells transformed with c-Myc exhibited increased apoptosis compared with untransformed control cells when treated with benzyloxycarbonyl-Leu-Leu-Phe-aldehyde (proteasome inhibitor II), a cell-permeable aldehyde inhibitor of the chymotrypsin-like activity of the proteasome. In contrast, we observed that epoxomycin induced apoptosis equally in both c-Myc-negative and c-Myc-positive rat fibroblasts. Furthermore, knockdown of c-Myc in HL60 cells did not affect sensitivity to epoxomycin. The explanation for the discrepancy between benzyloxycarbonyl-Leu-Leu-Phe-aldehyde and epoxomycin is unknown; however, aldehydes have been reported to also inhibit calpain and cathepsins (35) , which may explain the c-Myc dependence observed previously.
Wang et al. (19) previously demonstrated that PD150606 is highly specific for calpain inhibition as opposed to cathepsins, papain, trypsin, or thermolysin. Wang et al. (19) also reported that the K i value (concentration required for 50% inhibition) for PD150606 was 0.2 to 0.4 M for calpains 1 and 2, respectively; however, these measurements were performed in cell-free assays. We previously showed that the K i value for PD150606 in intact cells was 12.4 M (17), considerably higher than that reported by Wang et al. (19) . This difference may reflect access of the inhibitor to the interior of the cell. We also demonstrated that the nature of the PD150606 inhibition was "mixed" in character, affecting both substrate binding and maximal activity of the enzyme. Consequently, we observed reduced but significant activity of the enzyme in whole cells, even at an inhibitor concentration of 100 M. Furthermore, we have also observed that PD150606 loses inhibitory activity over time when incubated in aqueous medium (supplemental Fig. 1 ). Taken together, these characteristics of the inhibitor are likely responsible for the relatively high concentrations of the compound required for induction of apoptosis in both the rat fibroblasts and HL60 cells.
Calpain 2 appeared to be the prominent isoform in the rat fibroblast cells used in this study. Selective knockdown of calpain 2 results in decreased proteolysis of a variety of adhesionassociated molecules such as focal adhesion kinase, paxillin, spectrin, cortactin, and talin (29) . Calpain 2 knock-out mice are embryonic lethal suggesting an important role in cell function (21) . We observed that calpain activity was not well correlated with calpain protein levels. In fact, as shown in Fig. 1C , c-Mycnegative cells had the highest detectable levels of calpain 2 protein but the lowest levels of calpain activity. This may be due to the dominant negative regulatory role of calpastatin in these cells and the decrease in autocatalytic degradation of calpain in cells with high calpain activity (20, 36) . This observation highlights the importance of measuring calpain activity (17) in considering its role in cell function.
c-Myc regulates a multitude of genes associated with cell cycle and cell growth. It is therefore surprising that knock down of calpastatin in c-Myc-negative cells could restore cell growth to levels approaching that of c-Myc-positive cells. Previous attempts to identify genes that could complement the growth defect in c-Myc-negative cells were unsuccessful (37, 38) ; however, those strategies were not designed to knock down gene expression and therefore would not have picked up calpastatin. We do not yet know which calpain substrates are critical in mediating this effect; however, it is interesting to note that a variety of transcription factors are thought to be calpain targets (13) . Furthermore, it has been shown that one or two target genes can recapitulate c-Myc transforming activity (39 -46) . Therefore, these or other genes may be relevant targets for calpain.
We observed that calpain inhibitor treatment caused c-Mycpositive cells but not c-Myc-negative cells to detach from the plate. However, this property was not observed in calpastatin knocked down cells treated with calpain inhibitors (not shown) suggesting that calpain activity is required but not sufficient to maintain adhesion.
Incubation of c-Myc-positive cells on fibronectin-coated plates was found to protect the cells from both detachment and apoptosis induced by calpain inhibition. This phenomenon was observed when calpain was inhibited with PD150606 or when calpain activity was suppressed through the knockdown of CPNS1. These observations are consistent with previous reports documenting decreased fibronectin expression in c-Myc-overexpressing cells (22, 30, 31) , which we confirmed in this study (Fig. 7A) . However, it is unlikely that cell adhesion is the only target for calpain inhibitors in c-Myc-expressing cells because nonadherent HL60 cells are also sensitive to calpain inhibition. Rather, a more likely scenario is that in c-Myc-expressing fibroblasts, signals stimulated by adhesion (47) (48) (49) are sufficient to protect cells from the pro-apoptotic effects of calpain inhibition.
A hallmark of c-Myc-transformed cells is anchorage-independent cell growth (50, 51) . We observed that knockdown of calpastatin in c-Myc-negative cells conferred anchorage independence. This observation suggests that calpain is required for this phenotype and also raised the possibility that calpastatin could influence tumorigenicity. This was indeed confirmed when we observed that knockdown of calpastatin with shRNA could confer tumorigenicity to c-Myc-negative cells. It is interesting to note that growth of these cells in vivo exhibited an early delay compared with c-Myc-positive cells. This delay may be due to additional alterations in the cells or the emergence of clones with enhanced growth properties. These possibilities remain to be investigated.
Our observation that calpain inhibitors preferentially induce apoptosis in c-Myc-positive cells suggests that calpain inhibitors may have anti-cancer potential, particularly for tumor cells associated with dysregulated c-Myc. Other groups have also described situations where calpain inhibitors induce apoptosis (52) (53) (54) (55) (56) or suppress growth (57) . Calpain activity has been observed to be elevated in colorectal cancer cells compared with normal tissue (58) . Paradoxically, calpain inhibitors can also protect cells from cell death, particularly in situations characterized by Ca 2ϩ overload associated with disease states such as stroke or brain trauma (36) . Furthermore, Tan et al. (59) showed that primary cells deficient in calpain activity were both sensitized and de-sensitized to various apoptotic stimuli. A full understanding of the role and potential for calpain inhibitors will require additional investigation. However, our identification of a role for c-Myc in calpain inhibitor-induced apoptosis provides an important insight in this regard.
